Search Within

Malin Lisa Hultcrantz

  1. "Sean Devlin"
Formats
  1. Meeting Abstract (23)
  2. Journal Article (7)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Biostatistics Service (32)
  2. Center for Hematologic Malignancies (32)
  3. Department of Medicine (32)
  4. Epidemiology and Biostatistics (32)
  5. Hematologic Malignancies Research (32)
  6. Hematologic Malignancies, Division of (32)

More Groups

People
  1. Sean Devlin (32)
  2. Alexander Lesokhin (30)
  3. Sham Mailankody (30)
  4. Hani Hassoun (28)
  5. Neha Korde (28)
  6. Sergio Giralt (26)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (6)
  4. 2022 (3)
  5. 2021 (6)
  6. 2020 (4)

More Years

Publications
  1. Blood (15)
  2. Clinical Lymphoma, Myeloma and Leukemia (5)
  3. Journal of Clinical Oncology (3)
  4. American Journal of Hematology (1)
  5. Annals of Oncology (1)
  6. Biology of Blood and Marrow Transplantation (1)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. Elsevier Inc. (6)
  3. American Society of Clinical Oncology (3)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)
  6. John Wiley & Sons, Inc. (1)

More Publishers

Results (32)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma
    Journal Article

    Bal, S.; Landau, H. J.; Shah, G. L.; Scordo, M.; Dahi, P.; Lahoud, O. B.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Meeting Abstract

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Korde, N.; Lendvai, N.; Hassoun, H.; Lesokhin, A. M.; Lahoud, O. B.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
    Journal Article

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Chen, D.; Devlin, S. M.; more...
    PLoS ONE (2019)

    Fulltext@MSK | Save
  • MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Depth of response and outcomes in patients with multiple myeloma undergoing autologous stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Seier, K.; Devlin, S. M.; Chung, D. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; Lendvai, N.; Lesokhin, A. M.; Mailankody, S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • V(D)J sequence capture for DNA-based minimal residual disease detection in multiple myeloma
    Meeting Abstract

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Devlin, S. M.; Jacobsen, A.; more...
    Blood (2018)

    Fulltext@MSK | Save